Se­qens ma­jor­i­ty own­er look­ing to sell API mak­er amid record-high run in health­care val­u­a­tions: re­port

Three years af­ter it re­brand­ed from No­va­cap, Se­qens, a French phar­ma­ceu­ti­cal man­u­fac­tur­er and in­gre­di­ent sup­pli­er is re­port­ed­ly be­ing prepped for sale.

The sale comes as Se­qens’ pri­vate eq­ui­ty own­ers — its ma­jor­i­ty own­er is Eu­razeo — are hop­ing to cash in on the cur­rent high val­u­a­tions in the health­care mar­ket, Reuters re­port­ed Mon­day, cit­ing two un­named sources close to the mat­ter.

Eu­razeo, a French in­vest­ment firm, has charged JP Mor­gan with find­ing a buy­er for the com­pa­ny, the re­port said, which could be val­ued at up­wards of $2.4 bil­lion (2 bil­lion eu­ros). Se­qens makes and dis­trib­utes as­pirin and parac­eta­mol, among oth­er API — which brought in earn­ings of around $180.9 mil­lion (150 mil­lion eu­ros) in the com­pa­ny’s most re­cent fis­cal year. That means its sale val­ue could be 15 times that of its core earn­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER